Capital One Upgrades Outlook Therapeutics to Overweight, Announces $5 Price Target
Capital One Upgrades Outlook Therapeutics to Overweight, Announces $5 Price Target
Capital One將Outlook Therapeutics上調至增持,宣佈5美元的
Capital One analyst Zegbeh Jallah upgrades Outlook Therapeutics (NASDAQ:OTLK) from Equal-Weight to Overweight and announces $5 price target.
Capital One分析師澤格貝·賈拉將Outlook Therapeutics(納斯達克股票代碼:OTLK)從等重上調至增持,並宣佈了5美元的目標股價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。